Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis

• DOI: 10.1111/j.1572-0241.2002.06026.x
• Publication Date: 2004-08-11T09:14:12Z
• Authors: Chinyu Su; Bruce A. Salzberg; James D. Lewis; Julius J. Deren; Asher Kornbluth; David A. Katzka; Robert B. Stein; Douglas R. Adler; Gary R. Lichtenstein
• Keywords: Refractory (planetary science)

Tumor necrosis factor-alpha (TNF-alpha) is an important cytokine involved in the pathogenesis of inflammatory bowel disease. The monoclonal antibody to TNF-alpha, infliximab, effective treating Crohn's Preclinical studies suggest importance TNF-alpha ulcerative colitis (UC). We report effectiveness infliximab for UC and examine factors predictive response medication.Data from all patients receiving at four institutions were analyzed. Disease activity was determined by Activity Index.A total 27 with active received inpatient (37%) outpatient (63%) as single (52%) or multiple (two 15) infusions (48%). Twelve (44%) achieved remission six (22%) had partial response. Nine no response; five subsequently underwent colectomy. median time achieve 4 days duration 8 wk. 18 who responded experienced 19 relapses; these relapses (95%) successfully treated repeat infusions. Steroid-refractory less likely respond therapy than steroid-responsive (33% vs 83%; p = 0.026). No other infliximab. Two developed serious adverse events, including death one case.Preliminary evidence treatment UC, medically refractory severe Individuals are corticosteroids, however, may be unlikely A randomized controlled trial necessary further investigate efficacy UC.